^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1)

    i
    Other names: HLA-DPA1, Major Histocompatibility Complex, Class II, DP Alpha 1, HLA-DP1A, HLA Class II Histocompatibility Antigen, DP Alpha 1 Chain, MHC Class II DP3-Alpha, HLA-SB Alpha Chain, DP(W3), DP(W4), HLASB, MHC Class II Antigen DP Alpha Chain, MHC Class II HLA-DPA1 Antigen, MHC Class II DP Alpha Chain, MHC Class II Protein, MHC Class II DPA1, HLA-DPB1, HLA DPA1, HLA-DPA, HLADP, DPA1, PLT1
    1m
    Germline HLA heterozygosity is associated with decreased lung cancer risk. (PubMed, HGG Adv)
    Finally, analysis of the additive effects of HLA allele heterozygosity in smokers identified significant associations with several 4-digit HLA alleles, including HLA-B*08:01, HLA-A*01:01, HLA-C*07:01, HLA-DQA1*05:01, HLA-DRB1*03:01, and HLA-C*03:04. Our study provides additional evidence, with added histologic subtype information, that germline HLA-II heterozygosity is inversely associated with lung cancer risk.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    5ms
    Exploring therapeutic targets for hepatocellular carcinoma through druggable genes. (PubMed, Medicine (Baltimore))
    MR-, summary-data-based MR-, and co-localization-based approaches identified target genes associated with HCC risk, comprising 3 first-level targets (HLA-DPA1, MBTPS1, and TIMP3), 2 second-level targets (TNXB and HSD17B11), and also 4 tertiary targets (HLA-DPB1, PLD2, KLHL8, and TGFBR1). All in all, this research identifies several potential therapeutic targets relevant to the risk of HCC and provides new insights into the identification of therapeutic agents for the treatment of HCC.
    Journal
    |
    HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    6ms
    Spatial gene expression profiling identifies prognostic features of residual tumors after neoadjuvant chemotherapy in triple-negative breast cancer. (PubMed, Front Oncol)
    We identified some differentially expressed genes relevant to oncogenic signaling and immunosuppressive tumor-associated macrophages. These findings provide novel insights into factors affecting prognosis in patients with residual disease after NAC for early-stage TNBC.
    Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle) • S100A9 (S100 Calcium Binding Protein A9) • CHI3L1 (Chitinase 3-like 1) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • KRT14 (Keratin 14) • COL3A1 (Collagen Type III Alpha 1 Chain) • IFI27 (Interferon Alpha Inducible Protein 27) • AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding) • MMP7 (Matrix metallopeptidase 7) • MYLK (Myosin Light Chain Kinase) • PABPC1 (Poly(A) Binding Protein Cytoplasmic 1) • SERPINA3 (Serpin Family A Member 3) • TPM2 (Tropomyosin 2) • RPL22 (Ribosomal Protein L22)
    9ms
    Two Novel HLA-DPA1 Alleles Identified in a Triple Negative Breast Cancer Patient From Brazil. (PubMed, HLA)
    Identification of the novel alleles HLA-DPA1*02:142 and HLA-DPA1*01:03:01:92.
    Journal
    |
    HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1)
    over1year
    mRNA-seq-based analysis predicts: AEG-1 is a therapeutic target and immunotherapy biomarker for pan-cancer, including OSCC. (PubMed, Front Immunol)
    In conclusion, AEG-1 significantly correlates with prognosis and immune infiltration across various cancer types and holds potential as a novel prognostic immune biomarker for OSCC. This finding may facilitate the identification of patients who are most likely to benefit from adjuvant immunotherapy.
    Journal • IO biomarker • Pan tumor
    |
    CD74 (CD74 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • MTDH (Metadherin)
    over1year
    Cluster of Differentiation Markers and Human Leukocyte Antigen Expression in Chronic Lymphocytic Leukemia Patients: Correlations and Clinical Relevance. (PubMed, Curr Issues Mol Biol)
    The results indicate that several CD markers are statistically associated with different HLA alleles, specifically CD45 with HLA-C*07:01:01; CD79b with HLA-DPA1*02:01:02; CD23 with HLA-B*39:01:01; CD22 with HLA-B*49:01:01, HLA-C*07:01:01, HLA-DPB1*02:01:02, and HLA-DRB1*07:01:01; and CD81 with HLA-DPB1*04:02:01, HLA-DQA1*01:04:01, and HLA-DQB1*05:03:01. In conclusion, this research demonstrates significant statistical links between HLA genes and immunophenotypic markers in CLL patients, shedding new light on the immunological context of CLL.
    Journal
    |
    CD79B (CD79b Molecule) • CD22 (CD22 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • CD81 (CD81 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II) • HLA-C (Major Histocompatibility Complex, Class I, C)
    over1year
    HLA-DPB1 and DPA1 ~ DPB1 linkage mismatch affects the survival of recipients receiving HLA-14/14 matched unrelated donor HSCT. (PubMed, HLA)
    DPA1*02:02 ~ DPB1*05:01/DPA1*01:03 ~ DPB1*02:01 linkage mismatches showed no impact on outcomes. In conclusion, applying the DPA1 ~ DPB1 linkage mismatch analysis approach can identify different types of mismatches affecting transplant outcomes and provide valuable insight for selecting optimal donors for AML/MDS and ALL recipients.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    2years
    ncRNAs-mediated TIMELESS overexpression in lung adenocarcinoma correlates with reduced tumor immune cell infiltration and poor prognosis. (PubMed, PLoS One)
    TIMELESS expression in LUAD tumor tissues was significantly negatively correlated with neutrophil biomarkers, dendritic cell biomarkers (HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DPA1, CD1C) and an immunophenoscore that predicted outcomes associated with the use of immune checkpoint inhibitors. These findings imply that ncRNAs-mediated TIMELESS overexpression in LUAD tumor tissues correlated with poor prognosis, reduced immune cell infiltration in the tumor microenvironment, and poor response to immune checkpoint inhibitors.
    Journal • IO biomarker • Immune cell
    |
    CD4 (CD4 Molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • TIMELESS (Timeless Circadian Regulator) • CD1C (CD1c Molecule) • MIR4435-2HG (MIR4435-2 Host Gene)
    2years
    Correlation of PIM kinases with tumor immune microenvironment and clinical presentation of metastatic hormone-sensitive prostate cancer. (ASCO-GU 2024)
    These data indicate a strong association of PIM expression with increased MAPK activation score, T cell inflamed score, inflammatory, PSA, AR, MHC class I and MHC class II gene expression, and differential immune cell infiltration. However, this did not significantly translate to a worse clinical presentation of mHSPC. A better understanding of these differences with additional research may provide a rationale for tailored therapeutic approaches for PIM-expressing mHSPC.
    Clinical • Metastases
    |
    LDHA (Lactate dehydrogenase A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • B2M (Beta-2-microglobulin) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • IL2 (Interleukin 2) • PIM1 (Pim-1 Proto-Oncogene) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • PDGFB (Platelet Derived Growth Factor Subunit B) • IL1B (Interleukin 1, beta) • NDRG1 (N-Myc Downstream Regulated 1) • TAP1 (Transporter 1) • DDIT4 (DNA Damage Inducible Transcript 4) • HLA-C (Major Histocompatibility Complex, Class I, C) • PGK1 (Phosphoglycerate Kinase 1) • TNFSF13 (TNF Superfamily Member 13)
    |
    HIF1A expression • MHC-II expression
    2years
    The Human Leukemia Immunopeptidome Is Driven By Pathogenic Molecular Variant Biotypes (ASH 2023)
    The presence of neopeptide binding predicted improved mOS in patients with myeloid malignancies. Further investigation of the human leukemia immunopeptidome may provide additional prognostic significance above that of standard molecular and cytogenetic risk stratification.
    Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1)
    |
    TP53 mutation • FLT3 mutation • TMB-L
    2years
    Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile (ASH 2023)
    These findings show that the bone marrow microenvironment immune profile in MDS and CHIP likely plays a major role in the disease. Furthermore, this data suggests that this immune microenvironment is critical in CHIP and perhaps that therapeutic approaches supporting this immune microenvironment may help in preventing CHIP from progressing to MDS. The data also supports that AML is a disease that completely overwhelms the HLA immune system.
    IO biomarker
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • HLA-DRB5 (Major Histocompatibility Complex, Class II, DR Beta 5) • HLA-E (Major Histocompatibility Complex, Class I, E) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • HLA-C (Major Histocompatibility Complex, Class I, C) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)